Proof, across the world's most complex markets

A new women's healthcare company, launched in 2021, successfully influenced global policy by securing the first-ever G20 commitments on women's health. By building a strong evidence base and a broad stakeholder coalition, the company executed a relentless engagement strategy across three successive G20 presidencies (Indonesia, India, and Brazil). This proactive approach established the company as a key voice and achieved landmark policy wins on an international stage.

A global pharmaceutical company successfully built a unified corporate reputation across 50+ emerging markets by implementing a strategic corporate affairs blueprint. By combining a central expert team in its Singapore HQ with on-the-ground local support, the company enhanced stakeholder relations and transformed its crisis management framework. This agile approach enabled the business to navigate corporate restructurings and successfully launch a flagship Dengue vaccine in key Latin America and APAC markets.

A global healthcare company successfully navigated the complex APAC vaccine landscape by developing a robust framework for policy intelligence and market access. By leveraging well-connected local consultants and regional experts, the firm gained critical insights into vaccine policy, stakeholder attitudes, and procurement processes. The implementation of a regional dashboard provided leadership with real-time analysis, enabling the company to effectively influence policy and mitigate commercial risks in key Asia-Pacific markets.

From 2021 to 2024, a pharmaceutical company addressed challenges in Latin America’s self-care market—fragmentation and health-related misinformation—by launching a strategic communications campaign. Speyside developed tailored narratives and a regional strategy to promote over-the-counter medicines, disease awareness, and responsible self-care. The effort resulted in over 350 media clippings across top outlets and positioned company leaders and experts as credible voices, strengthening the company’s leadership in the region’s consumer healthcare space.

To support diabetes policy reform in Mexico, a pharmaceutical company worked with Speyside to go beyond glucose control and emphasize the prevention of cardiovascular and kidney complications. Speyside implemented a multi-phase strategy that included stakeholder mapping, policy analysis, communication campaigns, and workshops. The project engaged policy champions and strengthened collaboration between patient groups, health professionals, and policymakers—laying the groundwork for a national response that prioritizes early diagnosis, prevention, and better treatment outcomes.

A pharmaceutical company partnered with Speyside to improve awareness around hemophilia in Mexico, focusing on the challenges of treatment adherence. Speyside assessed the healthcare landscape, mapped stakeholders, and led educational initiatives to build advocacy capacity. The project produced a strategic policy brief, hosted symposiums, and launched an ambassador program. As a result, it identified key barriers, strengthened patient organizations, and laid the groundwork for sustained advocacy and improved health outcomes.

A pharmaceutical company sought to lead efforts in understanding Mexico’s healthcare landscape for Syncytial Respiratory Virus (SRV), especially to improve infant care. Speyside organized a focus group with medical experts and civil society, using stakeholder mapping and support materials to gather insights. The result was a final report with public policy recommendations. These insights helped the company understand challenges in the public healthcare system and provided a clear foundation for future advocacy and engagement with decision-makers.

In 2017, a pharmaceutical company specializing in rare diseases asked Speyside to support and strengthen Patient Advocacy Groups (PAGs) in Brazil, which at the time operated in isolation and lacked coordination. Speyside conducted surveys and interviews to identify weaknesses and training needs, later organizing a webinar on regulatory processes and a hands-on workshop on public policy and advocacy. As a result, PAGs aligned on shared advocacy goals for 2018 and developed a roadmap for joint action—laying the foundation for a stronger, more unified rare disease advocacy network in the country.

Speyside supported a pharmaceutical company in advancing cancer policies in Brazil and facilitating the inclusion of an innovative metastatic melanoma treatment in the public health system (SUS). The work involved regulatory and stakeholder analysis, engagement with decision-makers during CONITEC’s technology incorporation process, and continuous monitoring amid COVID-19 disruptions. These efforts positioned the product as one of the top two treatment options within CONITEC and provided the company with critical insights and ministry connections to support the incorporation process.